Chelsea Therapeutics International announced that the FDA has granted accelerated approval of Northera (droxidopa) for the treatment of symptomatic Neurogenic...
The FDA has issued a Complete Response Letter regarding the new drug application for Northera (droxidopa) from Chelsea Therapeutics for...
Chelsea Therapeutics International, Ltd. has received written guidance from the Director of the Office of New Drugs at the FDA...
The FDA Cardiovascular and Renal Drugs Advisory Committee voted 7-4 with 1 abstention and 1 non-vote to recommend approval of...
H. Lundbeck A/S and Chelsea Therapeutics International, Ltd. have announced that the companies have entered into a definitive agreement under...